Taltz (Subcutaneous)
Taltz (Subcutaneous) Uses, Dosage, Side Effects, Food Interaction and all others data.
Taltz (Subcutaneous) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Taltz (Subcutaneous) is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Taltz (Subcutaneous) is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
| Trade Name | Taltz (Subcutaneous) |
| Availability | Prescription only |
| Generic | Ixekizumab |
| Ixekizumab Other Names | Ixekizumab |
| Related Drugs | Taltz, Humira, Otezla, Cosentyx, Cimzia, prednisone, naproxen, methotrexate, Enbrel, Remicade |
| Type | |
| Formula | C6492H10012N1728O2028S46 |
| Weight | 146158.0 Da |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | USA |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Taltz (Subcutaneous) is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Taltz (Subcutaneous) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Taltz (Subcutaneous) is also used to associated treatment for these conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis
How Taltz (Subcutaneous) works
Taltz (Subcutaneous) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Toxicity
The most common adverse reactions associated with Taltz (Subcutaneous) treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
Food Interaction
No interactions found.Taltz (Subcutaneous) Drug Interaction
Unknown: aspirin, charcoal, celecoxib, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, carvedilol, glucose, diltiazem, glycerin, heparin, sodium iodide, ferrous sulfate, empagliflozin, arginine, levocarnitine, cysteine, furosemide, acetaminophen, cholecalciferol
Taltz (Subcutaneous) Disease Interaction
Moderate: infections, inflammatory bowel disease, tuberculosisMinor: renal/hepatic impairment
Volume of Distribution
The mean (geometric CV%) volume of distribution at steady-state was 7.11 L (29%) in subjects with plaque psoriasis.
Elimination Route
Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.
Half Life
13 days
Clearance
0.39 L/day
Innovators Monograph
You find simplified version here Taltz (Subcutaneous)
